Overview
- An international consensus announced in late May renamed polycystic ovarian syndrome to Polyendocrine Metabolic Ovarian Syndrome and set a staged three‑year rollout to update guidelines and disease coding.
- A national registry analysis of about 128,000 women with the condition and 587,000 without found a 32% higher risk of cardiovascular disease for those with PMOS and roughly a 40% higher risk for women with BMI under 25 who do not have type 2 diabetes.
- Clinicians warn that care for people with PMOS is often fragmented across gynaecology, dermatology and nutrition, which leads to missed opportunities for early detection of insulin resistance, high blood pressure and abnormal lipids.
- Doctors and professional groups in India are calling for routine metabolic and heart‑health screening for young urban women after studies showed rising prevalence in places such as Delhi‑NCR and national data show cardiovascular disease causes about 31% of deaths.
- The consensus keeps current Rotterdam diagnostic criteria in use for now and plans phased education and guideline updates through about 2028, so adoption and insurer coverage will vary while public awareness and integrated care pathways are developed.